Evidence map›Paper›PMID 37645764›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Risk of Alzheimer's Disease is Associated with Longitudinal Changes in Plasma Biomarkers in the Multiethnic Washington Heights, Inwood Columbia Aging Project Cohort.

Yian Gu, Lawrence S Honig, Min Suk Kang, Aanya Bahl, Danurys Sanchez, Dolly Reyes-Dumeyer, Jennifer J Manly, Rafael A Lantigua, Jeffrey L Dage, Adam M Brickman and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yian GuTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Lawrence S HonigTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Min Suk KangTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Aanya BahlDepartment of Epidemiology, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, New York, New York, USA.
Danurys SanchezTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Dolly Reyes-DumeyerTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Jennifer J ManlyTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Rafael A LantiguaDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, New York,New York, USA.
Jeffrey L DageStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Adam M BrickmanTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Badri N VardarajanTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
Richard MayeuxTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New, York, New York, USA.
NewYork–Presbyterian Hospital · USColumbia University · USIndiana University School of Medicine

Funding

Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
VASCULAR FACTORS AND MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASEP01AG007232 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SCHUPF, NICOLE · 1989 to 2008
$21.7M
Epidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic, Washington Heights, Inwood, Columbia Aging Project (WHICAP)R01AG072474 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, MANLY, JENNIFER JAIE · 2021 to 2025
$13.3M
Epidemiological Integration of Genetic Variants and Metabolomics Profiles in Washington Heights Columbia Aging ProjectRF1AG066107 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P, MILLER, GARY W · 2020 to 2022
$11.4M
Epidemiology of Biomarkers of Risk and Progression in LOADR01AG037212 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P, SCHUPF, NICOLE · 2010 to 2015
$10.1M
Genetic Epidemiology of Cerebrovascular Factors in Alzheimer's DiseaseRF1AG054023 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P · 2016 to 2018
$8.9M
The role of inflammation in the association between diet and Alzheimer's diseaseR01AG059013 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, YIAN · 2019 to 2023
$3.7M
Diet and Cognition within a Reserve frameworkR01AG061008 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, YIAN · 2020 to 2024
$3.3M
Epidemiological Integration of Genetic Variants and Metabolomics Profiles in Washington Heights Columbia Aging ProjectR01AG066107 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P, MILLER, GARY W · 2024 to 2024
$1.5M
NIA NIH HHS P01 AG007232NIA NIH HHS P30 AG066462NIA NIH HHS R01 AG037212NIA NIH HHS R01 AG059013NIA NIH HHS R01 AG061008NIA NIH HHS R01 AG066107NIA NIH HHS R01 AG072474NIA NIH HHS RF1 AG054023NIA NIH HHS RF1 AG066107
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) biomarkers can help differentiate cognitively unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. The role of AD biomarkers in predicting cognitive impairment and AD needs examination.

methodsIn 628 CU individuals from a multi-ethnic cohort, Aβ42, Aβ40, phosphorylated tau-181 (P-tau181), glial fibrillary acid protein (GFAP), and neurofilament light chain (NfL) were measured in plasma.

resultsHigher baseline levels of P-tau181/Aβ42 ratio were associated with increased risk of incident dementia. A biomarker pattern (with elevated Aβ42/Aβ40 but low P-tau181/Aβ42) was associated with decreased dementia risk. Compared to CU, participants who developed MCI or dementia had a rapid decrease in the biomarker pattern reflecting AD-specific pathological change. DISCUSSION: Elevated levels of AD biomarker P-tau181/Aβ42, by itself or combined with a low Aβ42/Aβ40 level, predicts clinically diagnosed AD. Individuals with a rapid change in these biomarkers may need close monitoring for the potential downward trajectory of cognition.

Indexed as

Alzheimer’s diseaseamyloidblood biomarkerscognitiondementiaGFAPHispanicneurofilament light chaintau

Identifiers

PMID37645764
PMCPMC10462222
OpenAlexW4385878323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.